Colistin monotherapy versus combination therapy for carbapenem-resistant organisms

KS Kaye, D Marchaim, V Thamlikitkul, Y Carmeli… - NEJM …, 2022 - evidence.nejm.org
Background Pneumonia and bloodstream infections (BSI) due to extensively drug-resistant
(XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem …
被引用次数：49 相关文章

Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms

KS Kaye, D Marchaim, V Thamlikitkul… - NEJM …, 2022 - scholarlycommons.henryford.com
BACKGROUND: Pneumonia and bloodstream infections (BSI) due to extensively drug-
resistant (XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem …

Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms

KS Kaye, D Marchaim, V Thamlikitkul… - NEJM …, 2022 - scholarlyworks.beaumont.org
BACKGROUND Pneumonia and bloodstream infections (BSI) due to extensively drug-
resistant (XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem …

Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms.

KS Kaye, D Marchaim, V Thamlikitkul, Y Carmeli… - NEJM …, 2022 - europepmc.org
Background Pneumonia and bloodstream infections (BSI) due to extensively drug-resistant
(XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem …

Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms

KS Kaye, D Marchaim, V Thamlikitkul… - NEJM …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Pneumonia and bloodstream infections (BSI) due to extensively drug-resistant
(XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem …
[HTML] nih.gov

[HTML][HTML] Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms

KS Kaye, D Marchaim, V Thamlikitkul, Y Carmeli… - NEJM …, 2023 - ncbi.nlm.nih.gov
BACKGROUND Pneumonia and bloodstream infections (BSI) due to extensively drug-
resistant (XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem …

Colistin Mono vs Combination Therapy for Carbapenem-Resistant Organisms

KS Kaye, M Dror, T Visanu, C Yehuda… - NEJM …, 2022 - iris.unicampania.it
Background: Background: Pneumonia and bloodstream infections (BSI) due to extensively
drug resistant (XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and …

Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms

KS Kaye, D Marchaim, V Thamlikitkul… - NEJM …, 2023 - iris.unicampania.it
Background: Pneumonia and bloodstream infections (BSI) due to extensively drug-resistant
(XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem …